SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

The treatment, which will be sold under the brand name Exdensur, is an “ultra-long-acting” version of a biologic treatment ...

A southwest Houston mother is accusing staff at her daughter's KIPP Mosaic Primary of failing to call 911 after the ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

A southwest Houston mother says staff at her eight-year-old daughter's school failed to call 911 when she suffered an asthma ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...